Methazolamide for essential voice tremor

Karen Busenbark; L. Ramig; C. Dromey; William C. Koller

doi:10.1212/WNL.47.5.1331

Methazolamide for essential voice tremor

Karen Busenbark
, L. Ramig
, C. Dromey
, William C. Koller

Research output: Contribution to journal › Article › peer-review

39 Scopus citations

Abstract

We studied the safety and efficacy of methazolamide (average dose 168 mg/day) in a placebo-controlled blinded investigation in nine patients with essential voice tremor. There were no significant differences for physician or patient clinical rating scores. Digital audio tape recordings showed no difference for amplitude modulation, but frequency modulation was significantly altered by methazolamide. Side effects were common with the drug. We conclude that methazolamide has limited usefulness in the treatment of essential voice tremor.

Original language	English
Pages (from-to)	1331-1332
Number of pages	2
Journal	Neurology
Volume	47
Issue number	5
DOIs	https://doi.org/10.1212/WNL.47.5.1331
State	Published - Nov 1996
Externally published	Yes

Access to Document

10.1212/WNL.47.5.1331

Cite this

@article{ca29641ef5064ee492e99bb8a45115a8,

title = "Methazolamide for essential voice tremor",

abstract = "We studied the safety and efficacy of methazolamide (average dose 168 mg/day) in a placebo-controlled blinded investigation in nine patients with essential voice tremor. There were no significant differences for physician or patient clinical rating scores. Digital audio tape recordings showed no difference for amplitude modulation, but frequency modulation was significantly altered by methazolamide. Side effects were common with the drug. We conclude that methazolamide has limited usefulness in the treatment of essential voice tremor.",

author = "Karen Busenbark and L. Ramig and C. Dromey and Koller, \{William C.\}",

year = "1996",

month = nov,

doi = "10.1212/WNL.47.5.1331",

language = "English",

volume = "47",

pages = "1331--1332",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams and Wilkins",

number = "5",

}

TY - JOUR

T1 - Methazolamide for essential voice tremor

AU - Busenbark, Karen

AU - Ramig, L.

AU - Dromey, C.

AU - Koller, William C.

PY - 1996/11

Y1 - 1996/11

N2 - We studied the safety and efficacy of methazolamide (average dose 168 mg/day) in a placebo-controlled blinded investigation in nine patients with essential voice tremor. There were no significant differences for physician or patient clinical rating scores. Digital audio tape recordings showed no difference for amplitude modulation, but frequency modulation was significantly altered by methazolamide. Side effects were common with the drug. We conclude that methazolamide has limited usefulness in the treatment of essential voice tremor.

AB - We studied the safety and efficacy of methazolamide (average dose 168 mg/day) in a placebo-controlled blinded investigation in nine patients with essential voice tremor. There were no significant differences for physician or patient clinical rating scores. Digital audio tape recordings showed no difference for amplitude modulation, but frequency modulation was significantly altered by methazolamide. Side effects were common with the drug. We conclude that methazolamide has limited usefulness in the treatment of essential voice tremor.

UR - https://www.scopus.com/pages/publications/0029985070

U2 - 10.1212/WNL.47.5.1331

DO - 10.1212/WNL.47.5.1331

M3 - Article

C2 - 8909454

AN - SCOPUS:0029985070

SN - 0028-3878

VL - 47

SP - 1331

EP - 1332

JO - Neurology

JF - Neurology

IS - 5

ER -

Methazolamide for essential voice tremor

Abstract

Access to Document

Fingerprint

Cite this